Benozol Eye Drop

Indications of Benozol Ophthalmic Solution

Brin Doze Mid-Eye Drop Suspension is presented as a monotherapy or as an adjunct to beta-blockers in the treatment of elevated intraocular pressure or increased intraocular pressure in open-angle glaucoma.

Pharmacology of Benozol Ophthalmic Solution

Carbonic anhydrase (CA) is an enzyme found in many tissues of the body, including the eyes. It catalyzes a reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. It exists in the form of several isoenzymes, the most active being carbonic anhydrase II (CAII), present mainly in red blood cells, but also in other tissues. Inhibition of carbonic anhydrase in the processes of the ciliary body of the eye reduces the secretion of aqueous humor, presumably by slowing the formation of bicarbonate ions with a subsequent reduction in sodium and fluid transport.

 After topical ocular administration, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucoma visual field loss.

Dosage & Administration of Benozol Ophthalmic Solution

The recommended dose is one drops of this eye drop in the conjunctival sac of the affected eye(s) twice daily. Some patients may have a better response with one drop three times a day. Shake well before use.

Interaction of Benozol Ophthalmic Solution

In patients treated with oral carbonic anhydrase inhibitors, high-dose salicylate treatment has a rare drug interaction. Therefore, the possibility of such drug interactions should be considered in patients receiving brinzolamide treatment.

Contraindications

It is contraindicated in patients who are hypersensitive to any component of this product.

Side Effects of Benozol Ophthalmic Solution

The reported side effects are blurred vision and a bitter, sour or unusual taste. Other side effects are blepharitis, dermatitis, dry eye, foreign body sensation, headache, congestion, eye discharge, eye discomfort, keratitis, eye pain, eye itching and rhinitis.

Pregnancy

Pregnancy category C. There are no adequately well-controlled studies in pregnant women. Burinjoramido 1% eye drops should be used during pregnancy only if its effectiveness justifies the potential risk to the fetus.

 Use during lactation: It is not known whether Burinjoramido 1% eye drops are excreted in breast milk. Therefore, nursing mothers should stop lactation or discontinue the drug depending on the importance of the drug to the mother.

Precautions

Carbonic anhydrase (CA) is an enzyme found in many tissues of the body, including the eyes. It catalyzes a reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. It exists in the form of several isoenzymes, the most active being carbonic anhydrase II (CAII), present mainly in red blood cells, but also in other tissues. Inhibition of carbonic anhydrase in the processes of the ciliary body of the eye reduces the secretion of aqueous humor, presumably by slowing the formation of bicarbonate ions with a subsequent reduction in sodium and fluid transport.

After topical ocular administration, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucoma visual field loss.

Therapeutic Class

Drugs for miotics and glaucoma

Storage Conditions

Store at room temperature & protect from light. Do not touch dropper tip to any surface. It is desirable that the contents should not be used more than four weeks after first opening of the bottle. Protect from freezing.